UPDATE – OraSure Technologies Appoints James A. Datin to Its Board of Directors
15 8월 2019 - 2:19AM
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of
care diagnostic tests and specimen collection devices, today
announced the appointment of James A. Datin, as a member of the
Company’s Board of Directors. Mr. Datin will serve as a Class
III Director with an initial term expiring at the Company’s 2021
Annual Meeting of Stockholders. He will also serve on the
Audit and the Compensation Committees of the Board.
“We are pleased to have this opportunity for Jim
to serve on our Board of Directors,” said Stephen S. Tang, Ph.D.,
President and Chief Executive Officer of OraSure Technologies. “His
executive leadership experience, along with his experience in
mergers and acquisitions, improving performance and facilitating
growth in the life science industry will enable him to be a strong
contributor to the Company as it executes against its
innovation-driven growth strategy.”
Mr. Datin, age 56, currently serves as the
President and Chief Executive Officer of BioAgilytix, LLC, a global
bioanalytical contract research organization supporting the
development of novel therapeutic biologics. Prior to
BioAgilytix, from August 2005 to June 2013 Mr. Datin served as the
Executive Vice President and Managing Director at Safeguard
Scientifics, Inc. (NYSE: SFE), a company focused on providing
capital and advice to technology-driven businesses in healthcare,
financial services and digital media. Prior to his tenure at
Safeguard, Mr. Datin served as the Chief Executive Officer of
TouchPoint Solutions, a software solutions provider. Prior to
joining TouchPoint, Mr. Datin served in executive positions for
Dendrite International and Isuta.
Mr. Datin previously served on the Boards of
Directors of Clarient (NASDAQ: CLRT), NuPathe Inc. (NASDAQ: PATH),
the University City Science Center (Philadelphia) and Laurate
Pharma.
Mr. Datin earned a B.B.A. at Marshall
University, an M.B.A. at the University of New Haven and an
Advanced Management Degree at The Wharton School at The University
of Pennsylvania.
About OraSure Technologies
OraSure Technologies is empowering the global
community to improve health and wellness by providing access to
accurate essential information. OraSure is a leader in the
development, manufacture and distribution of point-of-care
diagnostic tests, molecular collection devices and other
technologies designed to detect or diagnose critical medical
conditions. Its first-to-market, innovative products include rapid
tests for the detection of antibodies to HIV and Hepatitis C (HCV)
on the OraQuick® platform, sample self-collection and stabilization
products for molecular applications, and oral fluid laboratory
tests for detecting various drugs of abuse. Together with its
wholly-owned subsidiaries (DNA Genotek, CoreBiome and Novosanis),
OraSure provides its customers with value-added, end-to-end
solutions that encompass tools, diagnostics and services.
OraSure’s portfolio of products is sold globally to various
clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, research
institutions, distributors, government agencies, physicians’
offices, commercial and industrial entities and consumers. For more
information on OraSure Technologies, please visit
www.orasure.com.
Investor
Contact: Robert CucaChief Financial Officer610-882-1820
investorinfo@orasure.com |
Media Contact:
Jeanne MellVP Corporate
Communications484-353-1575media@orasure.com |
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024